Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic lung disease

- PMLiVE

Astellas makes gene therapy a core focus with $3bn Audentes buy

Deal includes a late-stage candidate for a rare disease

AstraZeneca AZ

AstraZeneca divests Seroquel rights to focus on key therapy areas

Second divestment to Germany-based Cheplapharm this year

AstraZeneca AZ

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

Will go head-to-head with rival Roche's Tecentriq if approved

- PMLiVE

Private equity firm backs Ferring gene therapy venture

Joint venture will focus on development of therapies for bladder cancer

- PMLiVE

AstraZeneca wins FDA approval for Calquence in chronic lymphoma

Takes the fight to AbbVie and J&J's lymphoma rival Imbruvica

- PMLiVE

Nucala works in rare inflammatory disease, says GSK

Company is planning to file for approval in indication next year

- PMLiVE

Solid Bio falls as FDA halts DMD trial over safety concerns

Shares in the biotech dropped dramatically following the announcement

- PMLiVE

Personalised medicine can improve treatment, but access still an issue

Barriers to access could harm uptake of potentially transformative therapies

AstraZeneca AZ

AstraZeneca launches $1bn Chinese investment fund

AZ is among the top investors in the country with a strong market presence

Daiichi Sankyo logo

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline

- PMLiVE

AZ’s Imfinzi combo scores in front-line lung cancer

Attempts to catch up to BMS and Merck in non-small cell lung cancer

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links